Enzo Biochem, Inc.
ENZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$16.44M
Close$
$-1.14
462.5% downside
Current Fair Value
462.5% downsideOvervalued by 462.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $16.44 Million |
|---|---|
| Enterprise Value | $-17,246,001.00 |
| Dividend Yield | $0.40 (-) |
| Earnings per Share | $-0.51 |
| Beta | 1.16 |
| Outstanding Shares | 52,403,000 |
Return
| Return on Equity | -48.58% |
|---|---|
| Return on Assets | -33.19% |
| Return on Invested Capital | -22.80% |
Valuation & Multiples
| P/E Ratio | -8.47 |
|---|---|
| PEG | 111.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -0.63 |
| Enterprise Value to EBIT | 1.63 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.17 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Enzo Biochem, Inc.
CEO: Elazar Rabbani